May 25, 2013
Rite Aid (NYSE: RAD) is the third-largest drugstore chain in the United States, with over 4,800 stores in 31 states. The company makes most of its money from the sale of prescription drugs, but it also sells non-medical items such as cosmetics and greeting cards. The company should benefit from the tailwind of an aging U.S. population; people over 54 use drugs at much higher rates than their younger counterparts. Rite Aid, however, faces increasing competition from non-traditional drug retailers. Most notable among these is Wal-Mart, which recently began selling over 360 generic drugs for only $4 per subscription. This is significantly less than RAD's prices and may put pressure on the company's drug margins. It also has implications for the company's higher margin front-store (beauty products, snacks, etc.) sales, which are heavily dependent on RAD's ability to cross-sell customers who come in for prescriptions.
(Read more at Wikinvest
) - Company Overview
- Business Financials
- Indebtedness
- FY2010 Q3 Earnings Summary
- FY2010 Q4 Earnings Summary
- FY2010 Full Year Earnings Summary
- FY2011 Q1 Earnings Summary
- FY2011 Q2 Earnings Summary
- FY2011 Q3 Earnings Summary
- Key Trends and Forces
- Aging Population
- Generic Prescription Drugs
- Reliance on Medicare and Medicaid
- Increasing Competition from Supermarkets
- When Major Drug Manufacturers Suffer, Retail Pharmacy Generics Prosper
- As RAD Continues to Feel the Effects of Falling Sales, RAD Focuses on Inventory Management
- Market Share
- Competition
- Reference

